Lumicell Accelerates Commercial Expansion of LumiSystem for Breast Cancer Detection
Lumicell, Inc., a life sciences company specializing in fluorescence-guided imaging technologies, is accelerating the commercial expansion of its LumiSystem platform in the U.S. breast lumpectomy market. LumiSystem, which includes the FDA-approved optical imaging agent LUMISIGHT and the Lumicell DVS fluorescence imaging device, is designed for the intraoperative detection of cancerous tissue within the resection cavity during breast-conserving surgery. Unlike traditional specimen-based approaches that evaluate tissue after removal, LumiSystem allows surgeons to interrogate the lumpectomy cavity in situ, identifying suspected residual disease in real-time. This enables immediate removal during the same operation. The company's commercial momentum includes implementation at a leading cancer center, aligning with its 2026 objectives to scale LumiSystem, drive revenue growth, and increase patient access. Clinical and real-world data, including a recent study from Stanford Health, continue to support the clinic...